Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$854K
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$2.9M
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$2.35M

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.14B+85.5%
Enterprise value$5.89B+88.1%
P/S9.9×+2.2×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemAmountAmount
2026 (remaining six months)$$13,425
202726,742
202826,742
202926,742
203026,742
Thereafter126,995
$$247,388

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?
Mirum Pharmaceuticals, Inc. (MIRM) reported finite-lived intangible assets - expected amortization expense (year one) of $26.74M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
Mirum Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) increased by 13.4% year-over-year, from $23.58M to $26.74M.
What does finite-lived intangible assets - expected amortization expense (year one) mean?
This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.

Ask your AI about Mirum Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude